JP6405382B2 - 胚移植 - Google Patents
胚移植 Download PDFInfo
- Publication number
- JP6405382B2 JP6405382B2 JP2016533950A JP2016533950A JP6405382B2 JP 6405382 B2 JP6405382 B2 JP 6405382B2 JP 2016533950 A JP2016533950 A JP 2016533950A JP 2016533950 A JP2016533950 A JP 2016533950A JP 6405382 B2 JP6405382 B2 JP 6405382B2
- Authority
- JP
- Japan
- Prior art keywords
- vaginal
- administration
- pessary
- female
- embryo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000001161 mammalian embryo Anatomy 0.000 title claims description 37
- 238000012546 transfer Methods 0.000 title description 20
- 239000000203 mixture Substances 0.000 claims description 80
- 102000004127 Cytokines Human genes 0.000 claims description 46
- 108090000695 Cytokines Proteins 0.000 claims description 46
- 210000000582 semen Anatomy 0.000 claims description 24
- 230000035935 pregnancy Effects 0.000 claims description 22
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 19
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 19
- -1 IL-2ra Proteins 0.000 claims description 18
- 230000009027 insemination Effects 0.000 claims description 18
- 210000001215 vagina Anatomy 0.000 claims description 16
- 102100023688 Eotaxin Human genes 0.000 claims description 15
- 101710139422 Eotaxin Proteins 0.000 claims description 15
- 108010065805 Interleukin-12 Proteins 0.000 claims description 15
- 102000013462 Interleukin-12 Human genes 0.000 claims description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 15
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 15
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 13
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 13
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 13
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 10
- 210000004291 uterus Anatomy 0.000 claims description 10
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 8
- 108010074328 Interferon-gamma Proteins 0.000 claims description 8
- 108010002335 Interleukin-9 Proteins 0.000 claims description 8
- 102000000585 Interleukin-9 Human genes 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 7
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 7
- 102100037850 Interferon gamma Human genes 0.000 claims description 7
- 102000003814 Interleukin-10 Human genes 0.000 claims description 7
- 108090000174 Interleukin-10 Proteins 0.000 claims description 7
- 108090001005 Interleukin-6 Proteins 0.000 claims description 7
- 102000004889 Interleukin-6 Human genes 0.000 claims description 7
- 102100023487 Lens fiber major intrinsic protein Human genes 0.000 claims description 7
- 108010047660 Mitochondrial intermediate peptidase Proteins 0.000 claims description 7
- 102000013691 Interleukin-17 Human genes 0.000 claims description 6
- 108050003558 Interleukin-17 Proteins 0.000 claims description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 6
- 230000006058 immune tolerance Effects 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 238000002513 implantation Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 102000004388 Interleukin-4 Human genes 0.000 claims description 4
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 102100023995 Beta-nerve growth factor Human genes 0.000 claims description 3
- 101710129634 Beta-nerve growth factor Proteins 0.000 claims description 3
- 102100021936 C-C motif chemokine 27 Human genes 0.000 claims description 3
- 101710112538 C-C motif chemokine 27 Proteins 0.000 claims description 3
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 3
- 101710155834 C-C motif chemokine 7 Proteins 0.000 claims description 3
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 3
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 claims description 3
- 108010014419 Chemokine CXCL1 Proteins 0.000 claims description 3
- 102000016950 Chemokine CXCL1 Human genes 0.000 claims description 3
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims description 3
- 102000006573 Chemokine CXCL12 Human genes 0.000 claims description 3
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims description 3
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 3
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 3
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims description 3
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 3
- 108010002386 Interleukin-3 Proteins 0.000 claims description 3
- 108010002586 Interleukin-7 Proteins 0.000 claims description 3
- 102100020880 Kit ligand Human genes 0.000 claims description 3
- 101710177504 Kit ligand Proteins 0.000 claims description 3
- 102000016267 Leptin Human genes 0.000 claims description 3
- 108010092277 Leptin Proteins 0.000 claims description 3
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 3
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 3
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 3
- 102000034655 MIF Human genes 0.000 claims description 3
- 108060004872 MIF Proteins 0.000 claims description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 108700012411 TNFSF10 Proteins 0.000 claims description 3
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 claims description 3
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 claims description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 3
- 229940039781 leptin Drugs 0.000 claims description 3
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims description 2
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940044952 vaginal foam Drugs 0.000 claims description 2
- 239000000259 vaginal foam Substances 0.000 claims description 2
- 229940044977 vaginal tablet Drugs 0.000 claims description 2
- 239000000003 vaginal tablet Substances 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 15
- 230000008774 maternal effect Effects 0.000 description 13
- 210000002257 embryonic structure Anatomy 0.000 description 12
- 230000013011 mating Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 230000012173 estrus Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000004720 fertilization Effects 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102000001326 Chemokine CCL4 Human genes 0.000 description 6
- 108010055165 Chemokine CCL4 Proteins 0.000 description 6
- 102000003816 Interleukin-13 Human genes 0.000 description 6
- 108090000176 Interleukin-13 Proteins 0.000 description 6
- 239000000227 bioadhesive Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 230000001850 reproductive effect Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000011859 microparticle Substances 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000005706 microflora Species 0.000 description 3
- 230000000955 neuroendocrine Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000007879 vasectomy Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003016 pheromone Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283083 Sirenia Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 230000032686 female pregnancy Effects 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940076155 protein modulator Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940044950 vaginal gel Drugs 0.000 description 1
- 239000000029 vaginal gel Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D19/00—Instruments or methods for reproduction or fertilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D19/00—Instruments or methods for reproduction or fertilisation
- A61D19/02—Instruments or methods for reproduction or fertilisation for artificial insemination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D19/00—Instruments or methods for reproduction or fertilisation
- A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/206—IL-9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1314452.2A GB201314452D0 (en) | 2013-08-13 | 2013-08-13 | Embryo implantation |
| GB1314452.2 | 2013-08-13 | ||
| PCT/GB2014/052450 WO2015022509A1 (en) | 2013-08-13 | 2014-08-11 | Embryo implantation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016529254A JP2016529254A (ja) | 2016-09-23 |
| JP2016529254A5 JP2016529254A5 (enExample) | 2017-09-14 |
| JP6405382B2 true JP6405382B2 (ja) | 2018-10-17 |
Family
ID=49262086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533950A Expired - Fee Related JP6405382B2 (ja) | 2013-08-13 | 2014-08-11 | 胚移植 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10159712B2 (enExample) |
| EP (1) | EP3033096B1 (enExample) |
| JP (1) | JP6405382B2 (enExample) |
| CN (1) | CN105555298B (enExample) |
| AU (1) | AU2014307714B2 (enExample) |
| CA (1) | CA2920373C (enExample) |
| DK (1) | DK3033096T3 (enExample) |
| ES (1) | ES2698969T3 (enExample) |
| GB (2) | GB201314452D0 (enExample) |
| PL (1) | PL3033096T3 (enExample) |
| PT (1) | PT3033096T (enExample) |
| SG (1) | SG11201600772XA (enExample) |
| WO (1) | WO2015022509A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
| GB201501302D0 (en) * | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
| US10722560B2 (en) * | 2015-04-03 | 2020-07-28 | Nanocell Ltd. | Compositions for remodeling extracellular matrix and methods of use thereof |
| GB201517523D0 (en) * | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
| KR102127290B1 (ko) * | 2018-09-06 | 2020-06-26 | 고려대학교 산학협력단 | Fgf2를 유효성분으로 포함하는 임신촉진용 조성물 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS563846B2 (enExample) | 1972-10-12 | 1981-01-27 | ||
| US4211769A (en) | 1977-08-24 | 1980-07-08 | Takeda Chemical Industries, Ltd. | Preparations for vaginal administration |
| US5395825A (en) * | 1993-03-10 | 1995-03-07 | Yale University | Fertility regulation with transforming growth factor β |
| GB9406463D0 (en) * | 1994-03-31 | 1994-05-25 | Medical Res Council | Cervical ripening |
| AU4652596A (en) | 1995-01-09 | 1996-07-31 | Atrix Laboratories, Inc. | Liquid polymer delivery system |
| AU6836896A (en) * | 1995-08-28 | 1997-03-19 | Toray Industries, Inc. | Fertility agent |
| AUPO550897A0 (en) * | 1997-03-06 | 1997-03-27 | Luminis Pty Limited | Treatment and diagnosis of an infertility condition |
| AU764479B2 (en) | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
| US6258998B1 (en) * | 1998-11-24 | 2001-07-10 | Infigen, Inc. | Method of cloning porcine animals |
| CA2373073A1 (en) | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
| CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US20090124690A1 (en) | 2000-04-03 | 2009-05-14 | Alberte Randall S | Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins |
| AU2001268711A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| US7173113B2 (en) | 2002-01-31 | 2007-02-06 | The Trustees Of Columbia University In The City Of New York | Long-acting hormone and growth factor compositions and uses thereof |
| WO2004007472A1 (ja) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ｃｃｒ４アンタゴニストおよびその医薬用途 |
| AU2002951531A0 (en) | 2002-09-20 | 2002-10-03 | The University Of Adelaide | Treatment and diagnosis of an infertility condition by measuring or inhibiting interferon-y |
| KR20050094832A (ko) * | 2002-12-31 | 2005-09-28 | 알투스 파마슈티컬스 인코포레이티드 | 단백질 결정과 이온성 중합체를 함유하는 복합체 |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| WO2005017192A2 (en) | 2003-08-14 | 2005-02-24 | The General Hospital Corporation | Screening for gestational disorders |
| CA2540838C (en) | 2003-10-03 | 2014-12-16 | Thorn Bioscience, Llc | Process for the synchronization of ovulation for timed breeding without heat detection |
| US8338373B2 (en) | 2003-10-24 | 2012-12-25 | Nora Therapeutics, Inc. | Method for reducing the risk of spontaneous abortion in a human female subject |
| WO2005115456A2 (en) | 2004-05-28 | 2005-12-08 | President And Fellows Of Harvard College | METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY |
| JP2008501035A (ja) * | 2004-05-28 | 2008-01-17 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 妊孕性関連障害の治療におけるｉｌ−１７の使用 |
| EP2465534B1 (en) * | 2004-06-10 | 2017-03-29 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2006001463A1 (ja) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| WO2007011759A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
| PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
| US7790463B2 (en) | 2006-02-02 | 2010-09-07 | Yale University | Methods of determining whether a pregnant woman is at risk of developing preeclampsia |
| WO2007113682A2 (en) | 2006-04-06 | 2007-10-11 | Novozymes Gropep Ltd | Tgf-beta pharmaceutical compositions |
| AU2007325465B2 (en) * | 2006-11-28 | 2013-09-05 | Pictor Limited | Assay membrane and method of use thereof |
| PT2101760E (pt) | 2006-12-08 | 2013-05-07 | Millennium Pharm Inc | Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa |
| WO2008070902A1 (en) * | 2006-12-11 | 2008-06-19 | Novozymes Biopharma Au Limited | Tgf-beta compositions for treating infertility |
| US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| WO2009010871A2 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Pyrazole derivatives as antagonists of adenosine a3 receptor |
| US20100144756A1 (en) | 2007-07-13 | 2010-06-10 | Bolea Christelle | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| JP4834699B2 (ja) | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| EP2183254B1 (en) | 2007-08-29 | 2017-06-21 | MethylGene Inc. | Inhibitors of protein tyrosine kinase activity |
| GB0806281D0 (en) | 2008-04-07 | 2008-05-14 | Univ Leeds | Markers of Oocyte viability |
| WO2009139784A1 (en) | 2008-05-13 | 2009-11-19 | Nora Therapeutics, Inc. | Human g-csf analogs and methods of making and using thereof |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| WO2010126528A1 (en) | 2009-05-01 | 2010-11-04 | Nora Therapeutics, Inc. | Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination |
| EP2443230B1 (en) * | 2009-06-18 | 2017-07-26 | Takara Bio Europe AB | 3D CULTURING SYSTEMS FOR GROWTH AND DIFFERENTIATION OF HUMAN PLURIPOTENT STEM (hPS) CELLS |
| US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| RU2012104214A (ru) | 2009-08-05 | 2013-09-10 | Верситек Лимитед | Противовирусные соединения и способы их получения и применения |
| AU2011256088B2 (en) | 2010-05-20 | 2015-03-26 | University Of Saskatchewan | Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal |
| ES2526124T3 (es) | 2010-06-16 | 2015-01-07 | Cymabay Therapeutics, Inc. | Agonistas del receptor GPR120 y sus usos |
| WO2012079032A2 (en) | 2010-12-09 | 2012-06-14 | Trana Discovery, Inc. | Compositions and methods of treating drug-resistant retroviral infections |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| ITTO20111183A1 (it) * | 2011-12-21 | 2013-06-22 | Univ Degli Studi Torino | Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia |
| ITMI20122063A1 (it) | 2012-12-03 | 2014-06-04 | Marco Sbracia | Gm-csf per l'utilizzo nella prevenzione dell'aborto spontaneo e del fallimento dell'impianto dell'embrione |
| GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
| WO2015081157A1 (en) | 2013-11-27 | 2015-06-04 | Jbs United Animal Health Ii Llc | Method and composition for synchronizing time of insemination in gilts |
| GB201501302D0 (en) | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
| GB201517523D0 (en) | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
-
2013
- 2013-08-13 GB GBGB1314452.2A patent/GB201314452D0/en not_active Ceased
-
2014
- 2014-08-11 JP JP2016533950A patent/JP6405382B2/ja not_active Expired - Fee Related
- 2014-08-11 CN CN201480052022.0A patent/CN105555298B/zh not_active Expired - Fee Related
- 2014-08-11 AU AU2014307714A patent/AU2014307714B2/en not_active Ceased
- 2014-08-11 ES ES14750630T patent/ES2698969T3/es active Active
- 2014-08-11 PL PL14750630T patent/PL3033096T3/pl unknown
- 2014-08-11 EP EP14750630.7A patent/EP3033096B1/en not_active Not-in-force
- 2014-08-11 WO PCT/GB2014/052450 patent/WO2015022509A1/en not_active Ceased
- 2014-08-11 PT PT14750630T patent/PT3033096T/pt unknown
- 2014-08-11 CA CA2920373A patent/CA2920373C/en not_active Expired - Fee Related
- 2014-08-11 DK DK14750630.7T patent/DK3033096T3/en active
- 2014-08-11 SG SG11201600772XA patent/SG11201600772XA/en unknown
- 2014-08-12 US US14/457,360 patent/US10159712B2/en not_active Expired - Fee Related
- 2014-08-12 GB GB1414258.2A patent/GB2521709B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014307714B2 (en) | 2019-04-18 |
| EP3033096A1 (en) | 2016-06-22 |
| AU2014307714A1 (en) | 2016-03-03 |
| GB201314452D0 (en) | 2013-09-25 |
| ES2698969T3 (es) | 2019-02-06 |
| PL3033096T3 (pl) | 2019-02-28 |
| CA2920373A1 (en) | 2015-02-19 |
| PT3033096T (pt) | 2018-12-03 |
| GB2521709B (en) | 2016-06-01 |
| CN105555298A (zh) | 2016-05-04 |
| US10159712B2 (en) | 2018-12-25 |
| SG11201600772XA (en) | 2016-02-26 |
| CA2920373C (en) | 2021-09-07 |
| CN105555298B (zh) | 2021-03-16 |
| US20150051441A1 (en) | 2015-02-19 |
| GB2521709A (en) | 2015-07-01 |
| EP3033096B1 (en) | 2018-08-29 |
| DK3033096T3 (en) | 2018-12-17 |
| JP2016529254A (ja) | 2016-09-23 |
| WO2015022509A1 (en) | 2015-02-19 |
| GB201414258D0 (en) | 2014-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Paulenz et al. | Effect of cervical and vaginal insemination with liquid semen stored at room temperature on fertility of goats | |
| Ungerfeld et al. | Reproductive biology of the pampas deer (Ozotoceros bezoarticus): a review | |
| JP2016529254A (ja) | 胚移植 | |
| US10588944B2 (en) | Methods and compositions for managing reproduction | |
| Johnston et al. | Using the koala (Phascolarctos cinereus) as a case study to illustrate the development of artificial breeding technology in marsupials: an update | |
| US10987406B2 (en) | Embryo implantation | |
| Bromfield | Interaction of semen with female reproductive tract tissues: what we know, what we guess and what we need to do | |
| Nordstoga et al. | Vaginal deposition of frozen-thawed semen in Norwegian dairy goats: comparison of single and double insemination with equal total number of spermatozoa | |
| Bello et al. | Some aspects of reproductive performance of Red Sokoto goat does post synchronization with prostaglandin F2-alpha and progesterone sponges. | |
| Tamang et al. | Yak Frozen Semen Production and Cryopreservation in Bhutan: A Technological Breakthrough | |
| Hafez | Introduction to comparative reproduction | |
| French | Relationship Between Vaginal pH and a Successful Pregnancy in Small Ruminant Recipients and the Effect of Environmental Factors on Pregnancy Rates Throughout Recipient Programming and Embryo Transfer | |
| Priskas et al. | Factors affecting pregnancy rate after cervical insemination in dairy sheep flocks | |
| Ambrose et al. | Breeding and management strategies to improve reproductive efficiency in dairy cattle | |
| Schulman et al. | Reproductive Techniques | |
| Bernhard | Transgenerational Effects of in utero Heat Stress on Reproduction in Pigs | |
| Williams | Genetics and reproductive science | |
| Grimwood et al. | Assessing Norplant as a contraceptive in female Rodrigues fruit bats at Jersey Zoo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170804 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170804 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180515 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180810 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180821 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180914 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6405382 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |